Validation and modification of the PANOMEN 3 classification for predicting long-term recurrence/progression and quality of life in patients with pituitary adenomas: a multicentre retrospective cohort study
Authors' conclusion
The PANOMEN 3 classification provides clinically relevant prognostic value for recurrence/progression and postoperative HRQoL in PAs. The inclusion of SCAs and refined proliferative criteria enhanced predictive accuracy and demonstrated its potential as a comprehensive risk stratification tool. Prospective studies, including non-surgical cohorts, are warranted to confirm its generalisability.
Study context
- Population
- Patients with pituitary adenomas surgically treated between January 2010 and December 2023
- Participants
- 804 patients
- Exposure
- Original PANOMEN 3 vs modified PANOMEN 3 classification vs Trouillas clinicopathological grading
- Outcome
- Recurrence/progression
- Follow-up
- Median 5.0 years
Main finding
As reported in the abstract
Patients with recurrence/progression
169 patients
21.0%
Observational data: associations, not effects.
Further findings
Health-related quality of life (HRQoL) (EQ-5D-3 L and EuroQol Visual Analogue Scale (EQ-VAS)) · preoperatively and six months postoperatively
- Higher PANOMEN 3 grade was associated with poorer HRQoL outcomes
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →